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Abstract: Peripheral blood stem cells from healthy donors mobilized by granulocyte
colony-stimulating factor (G-CSF) and harvested by leukapheresis are commonly used for allogeneic
stem cell transplantation. The frequency of severe graft versus host disease is similar for patients
receiving peripheral blood and bone marrow allografts, even though the blood grafts contain more
T cells, indicating mobilization-related immunoregulatory effects. The regulatory phosphoprotein
osteopontin was quantified in plasma samples from healthy donors before G-CSF treatment, after
four days of treatment immediately before and after leukapheresis, and 18–24 h after apheresis.
Myeloma patients received chemotherapy, combined with G-CSF, for stem cell mobilization and
plasma samples were prepared immediately before, immediately after, and 18–24 h after leukapheresis.
G-CSF treatment of healthy stem cell donors increased plasma osteopontin levels, and a further
increase was seen immediately after leukapheresis. The pre-apheresis levels were also increased in
myeloma patients compared to healthy individuals. Finally, in vivo G-CSF exposure did not alter
T cell expression of osteopontin ligand CD44, and in vitro osteopontin exposure induced only small
increases in anti-CD3- and anti-CD28-stimulated T cell proliferation. G-CSF treatment, followed
by leukapheresis, can increase systemic osteopontin levels, and this effect may contribute to the
immunomodulatory effects of G-CSF treatment.
Keywords: allogeneic transplantation; hematopoietic stem cell mobilization; granulocyte
colony-stimulating factor; osteopontin; apheresis
1. Introduction
Osteopontin is a glycosylated phosphoprotein synthesized and secreted by various cells [1].
The ability to interact with several cell surface receptors, including certain integrins and CD44, makes
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osteopontin a functional regulator of cell adhesion, migration, and survival for a wide range of
cells [1]. Binding of osteopontin to the intracellular part of CD44 is important for cytoskeletal
functions [2,3], transcriptional regulation, and anti-apoptotic signaling in normal and malignant
cells [1,4–6]. Finally, osteopontin is important for normal hematopoiesis and is a component of the
hematopoietic stem cell niche, where it regulates the location and cycling of normal stem cells [7,8].
Osteopontin is widely expressed by immunocompetent cells and upregulated both during
inflammation and in various tumors [1,9–15]. It has pro-inflammatory effects by stimulating
chemotaxis of various immunocompetent cells and by increasing pro-inflammatory cytokine release
from macrophages [9] and expression of antigen-presenting and costimulatory molecules by dendritic
cells [16]. It is also important for B cell proliferation and immunoglobulin production and is released by
activated B cells and T cells as a Th1-associated cytokine [17–19]. However, osteopontin may also have
anti-inflammatory effects [1], as observed both in animal models [19,20] and human disease [20,21].
Osteopontin is also important for growth regulation of acute lymphoblastic, and probably also
acute myeloid leukemia, cells located at the endosteal stem cell niche [22,23]. Studies in humans
have demonstrated that plasma osteopontin levels can reflect local inflammation [24] as well as tumor
hypoxia and, thereby, chemo-sensitivity [25].
Systemic administration of granulocyte colony-stimulating factor (G-CSF) is commonly applied
to mobilize hematopoietic stem cells for collection by leukapheresis [26–28]. Several apheresis systems
have been developed for efficient harvesting of mononuclear cells [29–31]. Peripheral blood stem
cell grafts are widely used for allogeneic and autologous hematopoietic stem cell transplantation
(allo- and auto-HSCT) in hematological diseases, solid tumors and immune disorders [26,32–36], and
increasingly in autoimmune and non-malignant gastrointestinal diseases [37–39]. Additionally, G-CSF
mobilized progenitor cells are applicable in regenerative medicine and immunotherapy, and have, e.g.,
been tried in coronary and limb ischemia, as a possible source for differentiation of dendritic cells and
for isolation of mesenchymal stromal cells [40–44].
One important complication associated with allo-HSCT is acute graft versus host disease (acute
GVHD). The risk of acute GVHD seems to be similar for peripheral blood and bone marrow
allografts [45], suggesting that the potentially adverse effect of the larger number of donor T cells in
peripheral blood allografts is counteracted by immunomodulation of graft T cells during mobilization
or harvesting.
Animal models suggest that osteopontin stimulates CD8+ T cell-mediated GVHD [46]. This effect
may be caused either by pre-transplant modulation of immunocompetent cells in the allogeneic
stem cell grafts, or by post-transplant modulation caused by osteopontin in the graft supernatant or
osteopontin released in the recipient. Osteopontin has several immunomodulatory effects, and in
this context we investigated the levels of osteopontin in autologous and allogeneic stem cell donors
and stem cell grafts during mobilization/harvesting and in allogeneic stem cell recipients following
graft infusion.
2. Results
2.1. Plasma Osteopontin Levels of Healthy Stem Cell Donors Increase during Granulocyte Colony-Stimulating
Factor (G-CSF) Treatment and Reach a Maximal Level Immediately Following Stem Cell Harvesting
by Leukapheresis
The median plasma osteopontin levels in healthy allogeneic stem cell donors prior to G-CSF
therapy was 45 ng/mL (variation range: 27–62 ng/mL), see Table 1 and Figure 1. During G-CSF
treatment, and immediately prior to leukapheresis, the osteopontin concentration in the stem cell
donors was increased to a median level of 50 ng/mL (range: 19–75 ng/mL, p = 0.008). The healthy
allogeneic stem cell donors were compared to a group of 15 healthy platelet donors who did not receive
any kind of treatment prior to the apheresis. These healthy platelet donors showed no significant
differences compared to the healthy stem cell donors with respect to age, gender distribution, or
baseline white blood cell counts (Table 2). The pre-apheresis osteopontin concentrations of the platelet
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donors (median 44 ng/mL; range: 28–60 ng/mL) did not differ from the pre-treatment levels of the
allogeneic stem cell donors either (Table 1).
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and (iii) in allotransplanted patients 8–12 h prior to start of stem cell infusion and 12–16 h after 
infusion; (Lower part) Plasma G-CSF concentrations are given for allogeneic stem cell donors prior to 
and after G-CSF treatment and for autologous stem cell donors only after the G-CSF therapy. All 
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Allogeneic stem cell donors G-CSF stimulation 50 (22–241) 10,780 (3687–31,947) 0.0003 6673 (1704–21,152) 
Autologous stem cell donors G-CSF stimulation Not determined 18,366 (9861–46,314) Not determined 12,906 (8863–41,139) 
1 The osteopontin values measured in platelet concentrate supernatants were adjusted for dilution of 
the products with platelet additive solution (37% plasma, 63% T-sol). NS, not significant. 
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Figure 1. Plasma osteopontin levels in healthy allogeneic stem cell donors during stem cell mobilization
and harvesting. Peripheral blood plasma osteopontin concentrations were determined prior to
stimulation with granulocyte colony-stimulating factor (G-CSF) (A), after stem cell mobilization and
i mediately prior to apheresis (B), immediately after apheresis (C) and approximately 24 h after start
of apheresis (D).
Table 1. The effect of granulocyte colony-stimulating factor (G-CSF) treatment, apheresis procedures
and allogeneic ste cell transplantation on plas a osteopontin (OPN; Upper part) and G-CSF
(Lo er part) concentration. (Upper part) Fro the top, the plas a OP levels are presented for the
four study groups: (i) prior to and after -CSF treat ent of allogeneic ste cell donors; (ii) i ediately
before and after apheresis and in the apheresis product for each study group undergoing apheresis;
and (iii) in allotransplanted patients 8–12 h prior to start of stem cell infusion and 12–16 h after infusion;
(Lower part) Plasma G-CSF concentrations are given for allogeneic stem cell donors prior to and after
G-CSF treatment and for autologous stem cell donors only after the G-CSF therapy. All concentrations
are given as medians with variatio ranges in parentheses.
Patients/Donors Procedure Pre-ProcedureOPN (ng/mL)
Post-Procedure
OPN (ng/mL) p Value
Apheresis Product
OPN (ng/mL)
Allogeneic stem cell donors G-CSF stimulation 45 (27–62) 50 (19–75) 0.008 -
Stem cell apheresis 50 (19–75) 56 (31–87) 0.006 53 (29–73)
Autologous stem cell do rs te cell apheresis 89 (41–356) 109 (55–473) 0.008 86 (7–328)
Healthy platelet donors Platelet apheresis 44 (28–60) 46 (33–56) NS 48 (25–75) 1
Allogeneic HSC recipients Allogeneic stem celltranspla tation 126 (80–438) 103 (72–260) NS Not applicable
Patients/Donors Procedure Pre-ProcedureG-CSF (pg/mL)
Post-Procedure
G-CSF (pg/mL) p Value
Apheresis Product
G-CSF (pg/mL)
Allogeneic stem cell donors G-CSF stimulation 50 (22–241) 10,780 (3687–31,947) 0.0003 6673 (1704–21,152)
Autologous stem cell donors G-CSF stimulation Not determined 18,366 (9861–46,314) Not determined 12,906 (8863–41,139)
1 The osteopo tin values meas red in platelet concentrate supernatants were adjusted for ilution of the
products with platelet additive solution (37% plasma, 63% T-sol). NS, not significant.
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Table 2. Clinical and biological characteristics of healthy stem cell donors, autotransplanted myeloma
patients, healthy platelet donors, and allotransplant recipients. Number of individuals, age, and
gender (M: male, F: female) are presented for each study group. Median basal white blood cell
counts (WBC ˆ 109/L) are given for the study groups undergoing apheresis. White blood cell counts
and peripheral blood (PB) concentrations of CD34+ stem cells before start of apheresis and yield of
CD34+ stem cells are given for G-CSF stimulated allogeneic and autologous donors (multiple myeloma
patients). All values are presented as medians with the variation ranges given in parentheses.
Group Age Gender (M/F)













donors (n = 22) 51 (25–77) 14/8 5.9 (3.1–13.4) 46.0 (30.1–76.3) 44.1 (16.7–147.8) 5.4 (0.8–22.4)
Autologous stem
cell donors (n = 15) 57 (44–67) 9/6 5.4 (2.5–9.0) 10.8 (2.7–43.7) 39.9 (9.7–175.0) 5.3 (1.1–27.9)
Platelet donors
(n = 15) 47 (26–62) 8/7 6.0 (4.7–13.5) - - -
Allogeneic HSCT
recipients (n = 16) 47 (35–63) 7/9 - - - -
HSCT, hematopoietic stem cell transplantation.
The G-CSF-treated allogeneic stem cell donors showed a further increase of the median
osteopontin concentration to 56 ng/mL (range: 31–87 ng/mL, p = 0.008, Table 1) immediately after
leukapheresis, but 18–24 h after start of apheresis the median level had declined to 54 ng/mL (range:
29–76 ng/mL, p = 0.014, Figure 1). In contrast, the control group of healthy platelet donors showed
stable osteopontin levels throughout the observation period without significant altered concentrations
immediately after apheresis or 18–24 h after start of apheresis (Table 1).
Plasma G-CSF concentrations in allogeneic stem cell donors prior to and after mobilization were
also investigated. The median pre-treatment G-CSF level was 50 pg/mL (range: 22–241 pg/mL) and
after four days of G-CSF it was 10,780 pg/mL (range: 3687–31,947 pg/mL); see lower part of Table 1.
G-CSF and osteopontin levels then showed no significant correlation.
There were no significant associations between osteopontin plasma levels and apheresis time
(median: 305 min; range: 231–377 min) the absolute number of total blood volumes processed during
apheresis (median: 3.6; range: 1.6–6.6), or apheresis device applied.
2.2. Plasma Osteopontin Levels Show an Inverse Correlation with Peripheral Blood Neutrophil Levels during
G-CSF Therapy but No Association with Peripheral Blood Levels or Yields of CD34+ Cells
We used simple linear regression analyses with one way analysis of variance (ANOVA) to
study the correlation between healthy stem cell donor osteopontin levels (all donors included in the
analysis) and the corresponding peripheral blood levels of total leukocytes (Table 2) and leukocyte
subsets. Plasma osteopontin levels immediately prior to leukapheresis showed significant inverse
correlations with the corresponding peripheral blood neutrophil counts (median: 38.5 ˆ 109/L;
range: 24.3–66.4 ˆ 109/L; R2 = 0.381; p = 0.002) and total peripheral blood leukocyte counts (median:
46.0 ˆ 109/L; range: 30.1´76.3 ˆ 109/L; R2 = 0.366; p = 0.003). With this exception, there were no
significant associations between osteopontin levels and the total leukocyte counts or the levels of
neutrophils, monocytes, total lymphocytes, CD3+ lymphocytes, or CD34+ cells in peripheral blood or
in the stem cell graft at any other time point.
2.3. Myeloma Patients (Autologous Stem Cell Donors) Show Increased Plasma Osteopontin Levels after G-CSF
Therapy Compared with Healthy Allogeneic Stem Cell Donors
Plasma samples from myeloma patients receiving G-CSF therapy for mobilization of autologous
stem cells were available only immediately before leukapheresis (after five days of G-CSF treatment);
the plasma osteopontin levels then showed a wide variation and were significantly increased for
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the myeloma patients (median 89 ng/mL; range 41–356 ng/mL) compared with the pre-apheresis
levels of the healthy stem cell donors (Mann-Whitney U test, p = 0.001). As presented in Table 1
(lower part), the pre-harvesting G-CSF levels were also significantly higher for myeloma patients
(median 18,366 pg/mL; range 9861–46,314 pg/mL) than for the healthy stem cell donors (median:
10,780 pg/mL; range: 3687–31,947 pg/mL; p = 0.005). There was no significant correlation between
pre-harvesting G-CSF and osteopontin plasma levels in the myeloma patients. As shown in Table 1 and
Figure 2, myeloma patients had a significant increase in plasma osteopontin level during apheresis,
but the increase in median osteopontin level 24 h after apheresis did not reach statistical significance.
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Figure 2. Plasma osteopontin levels in autologous stem cell donors (myeloma patients) after stem cell
mobilization and immediately prior to apheresis (B), immediately after apheresis (C) and approximately
24 h after start of apheresis (D).
2.4. Osteopontin Levels Are Higher in Autografts from Myeloma Patients than in Allografts from Healthy Stem
Cell Donors
We then compared osteopontin concentrations in the apheresis products from autologous and
allogeneic stem cell donors and healthy platelet donors. Autologous stem cell grafts from myeloma
patients showed significantly higher supernatant osteopontin levels than the allografts (p = 0.002) and
the platelet concentrates (p = 0.005); the results are summarized in Table 1 and presented in detail in
Figure 3. The osteopontin levels in auto- and allografts were higher than unstimulated plasma levels in
autologous and allogenic donors, but did not differ significantly from the corresponding plasma levels
during G-CSF therapy. Due to dilution with platelet additive solution as described in the experimental
section, the osteopontin levels in platelet concentrates were lower than the corresponding plasma
levels in the platelet donors, and low compared to allogeneic and autologous stem cell grafts (median:
18 ng/mL; range: 10–28 ng/mL). The patients treated with the platelet concentrates thus received
relatively low amounts of osteopontin during platelet infusion. However, after correction for the
dilution factor, there was no significant difference between osteopontin levels in platelet concentrates
and stem cell grafts from healthy donors or between platelet concentrates and peripheral blood samples
from the platelet donors (Table 1, Figure 3).
Int. J. Mol. Sci. 2016, 17, 1158 6 of 17
Int. J. Mol. Sci. 2016, 17, 1158 6 of 17 
 
 
Figure 3. Osteopontin levels in apheresis products, i.e., peripheral blood stem cell grafts and platelet 
concentrates. The osteopontin levels were determined in allogeneic stem cell products from  
G-CSF-mobilized healthy stem cell donors (n = 22), autologous stem cell products derived from 
myeloma patients mobilized by chemotherapy plus G-CSF (n = 15), and platelet concentrates from 
unstimulated healthy platelet donors (n = 15). The osteopontin levels measured in platelet 
concentrate supernatants were adjusted for dilution of the products with platelet additive solution 
(37% plasma, 63% solution). 
2.5. Pretransplant Osteopontin Levels of Allotransplant Recipients Are Increased and the High Levels Are Not 
Altered Following the Infusion of Osteopontin-Containing Stem Cell Grafts 
The pre-transplant osteopontin levels in allotransplant recipients were high (median: 126 ng/mL; 
range: 80–438 ng/mL) and were significantly higher than the levels in healthy individuals  
(p < 0.001; see Table 1), and even higher than for the myeloma patients (p = 0.02). The infusion of the 
osteopontin-containing allograft did not alter the plasma levels significantly; the levels remained 
high in the allotransplant recipients both when tested one day post-transplant and for eight patients 
also tested later after the transplantation (median: six days after infusion; range: 4–13 days). 
Additional analyses showed no association between recipient osteopontin plasma levels  
(Table 1) and (i) patient age and gender; (Table 2) (ii) allograft content of leukocytes, CD34+ stem 
cells, CD3+ T cells, neutrophils, monocytes, lymphocytes or platelets measured as absolute numbers 
or as the number of cells per kg patient body weight (Table 3). 
As presented in Table 3, the median time until neutrophil reconstitution with peripheral blood 
neutrophil counts above 0.5 × 109/L on the first of three consecutive days was day +17 (range: day +13 
to +28). Furthermore, the median time of platelet counts above 50 × 109/L for the first of three 
consecutive days was day +15 (range: day +11 to +39). There was no significant association between 
osteopontin levels and time until hematopoietic reconstitution. Finally, for the 16 patients 
investigated acute GVHD grade II–IV was seen in two patients, early death before day +100 in four 
patients, chronic GVHD in nine patients, and leukemia relapse in four patients. These observations 
suggest that our 16 patients are representative for allotransplanted patients. 
  
Figure 3. Osteopontin levels in apheresis products, i.e., peripheral blood stem cell grafts and
platelet concentrates. The osteopontin levels were determined in allogeneic stem cell products from
G-CSF-mobilized healthy stem cell donors (n = 22), autologous stem cell products derived from
myeloma patients mobilized by chemotherapy plus G-CSF (n = 15), and platelet concentrates from
unstimulated healthy platelet donors (n = 15). The osteopontin levels measured in platelet concentrate
supernatants were adjusted for dilution of the products with platelet additive solution (37% plasma,
63% solution).
2.5. Pretransplant Osteopontin Levels of Allotransplant Recipients Are Increased and the High Levels Are Not
Altered Following the Infusion of Osteopontin-Containing Stem Cell Grafts
The pre-transplant osteopontin levels in allotransplant recipients ere high ( edian: 126 ng/ L;
range: 80–438 ng/mL) and were significantly higher than the levels in healthy individuals (p < 0.001;
see Table 1), and even higher than for the myelo a patients (p = 0.02). The infusion of the
osteopontin-containing allograft did not alter the plas a levels significantly; the levels re ained
high in the allotransplant recipients both hen tested one day post-transplant and for eight patients
also tested later after the transplantation ( edian: six days after infusion; range: 4–13 days).
Additional analyses showed no association between recipient osteopontin plasma levels (Table 1)
and (i) patient age and gender; (Table 2) (ii) allograft content of leukocytes, CD34+ stem cells, CD3+
T cells, neutrophils, monocytes, lymphocytes or platelets measured as absolute numbers or as the
number of cells per kg patient body weight (Table 3).
As presented in Table 3, the edian ti e until neutrophil reconstitution with peripheral blood
neutrophil counts above 0.5 ˆ 109/L on the first of three consecutive days was day +17 (range: day +13
to +28). Further ore, the edian ti e of platelet counts above 50 ˆ 109/L for the first of three
consecutive days was day +15 (range: day +11 to +39). There was no significant association between
osteopontin levels and time until hematopoietic reconstitution. Finally, for the 16 patients investigated
acute GVHD grade II–IV was seen in two patients, early death before day +100 in four patients, chronic
GVHD in nine patients, and leukemia relapse in four patients. These observations suggest that our
16 patients are representative for allotransplanted patients.
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Table 3. Allogeneic stem cell grafts derived from healthy donors; the levels of various cells in the grafts
and the post-transplant clinical course of the allotransplant recipients. The cell content of the stem cell
grafts infused to 16 allotransplant recipients is presented as the absolute numbers in the graft (graft
content) and as the infused cell doses per kg (infused cells).
Cell Type Graft Content (ˆ108) Infused Cells (ˆ106/kg) Post-Transplant Course 1
Total WBC 791 (342–2495) 109 (376–3054) Neutrophil reconstitution 17 (13–28)
CD34+ stem cells 4.6 (2.4–6.7) 5.5 (3.3–6.8) Platelet reconstitution 15 (11–39)
CD3+ T cells 278 (71–490) 39 (10–61) aGVHD 2/16
Neutrophils 285 (112–1048) 45 (15–133) cGVHD 9/16
Monocytes 127 (18–563) 16 (3–69) Early death 4/16
Lymphocytes 346 (105–759) 50 (14–96) Relapse 4/16
Platelets 7068 (3176–11,449) 9607 (3655–14,260) - -
1 Neutrophil and platelet reconstitution is given as the first of three consecutive days after the transplantation
with neutrophil counts above 0.5 ˆ 109/L and platelet transfusion independence with platelet counts above
50 ˆ 109/L. aGVHD: acute graft versus host disease grade II–IV, cGVHD: chronic graft versus host disease,
early death: defined as death before day +100 after transplantation, WBC: white blood cell count. All values
are presented as medians with the variation ranges given in parentheses or as fractions of the total number of
16 patients.
2.6. T and B Lymphocytes Show High Expression of the CD44 Osteopontin Receptor and these High Levels Are
Maintained during Stem Cell Mobilization and Harvesting
Interaction between osteopontin and the CD44 receptor mediates chemotaxis of lymphocytes and
macrophages [47]. We investigated the expression of CD44 by viable donor lymphocytes during stem
cell mobilization and harvesting; the receptor was generally highly expressed and all comparisons
are therefore based on the mean fluorescence intensity (MFI), see Figure 4. In CD19+ B cells MFI
was reduced from 31,869 to 25,519 (mean values, n = 15) during G-CSF stimulation (p = 0.022).
No significant G-CSF induced change in CD44 expression was detected in CD3+ T cell populations;
neither was there any significant effect of apheresis on CD44 expression in T and B cells. T cell and
B cell CD44-APC MFI did not show any significant correlation to plasma levels of osteopontin or
G-CSF at any sampling point.
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Figure 4. Expression of CD44 in unstimulated (grey-colored bars) and in vivo G-CSF stimulated
(black-colored bars) peripheral blood leukocytes from healthy allogeneic stem cell donors. The results
are presented as the mean fluorescence intensity (MFI) given as mean values ˘ standard error
of the mean (SEM). (Left): The results for CD19+ B cells and CD3+ T cells with CD4+ and
CD8+ main subsets are shown; (Middle): CD4+ and CD8+ naïve (CD45RA+) T cell subsets are
compared with the corresponding T cell memory (CD45RA´) subsets and with T regulatory type
1 (Tr1) cells (CD4+ CD45RA´CD49b+ LAG-3+); (Right): Transitional B cells (CD19+CD24hiCD38hi)
together with mature (CD19+CD24+CD38+) a d memory (CD19+CD24hi38´) B-cells and plasmablasts
(CD19+CD24lowCD38hi) are presented. Statistically significant differences are indicated (** p = 0.001,
* p = 0.05).
Int. J. Mol. Sci. 2016, 17, 1158 8 of 17
CD44 expression was consistently higher for CD3+ T cells than for CD19+ B cells; as expected,
both CD4+ and CD8+ CD45RA´ memory T cells showed significantly higher CD44 expression than
CD45RA+ naïve T cells (Figure 4). Particularly high CD44 expression was found in the subset of
CD49b+ LAG-3+ Tr1 cells (lymphocyte activation gene-3 positive T regulatory type 1 cells) [48].
We also compared CD44 expression in the main CD19+ B cell subsets [49], in unstimulated and
G-CSF stimulated peripheral blood mononuclear cells (PBMC) samples. Compared to the CD24+CD38+
mature subset, transitional CD24hiCD38hi cells showed significantly lower and CD24hi38´ memory
B cells significantly higher CD44 expression. CD19+CD24lowCD38hi plasmablasts showed high CD44
expression similar to B memory cells [50].
To summarize, in vivo G-CSF therapy resulted in a modest reduction in CD44 expression in B cells
exclusively, and apheresis procedures did not alter T and B cell CD44 expression significantly.
2.7. Osteopontin Causes a Minor Increase of in Vitro Proliferative T Cell Responses
The effect of exogenous osteopontin on T cell proliferative responses was investigated for eight
healthy individuals (Figure 5). PBMC were cultured in vitro in the presence of anti-CD3 and anti-CD28.
We compared the proliferative responses for cultures prepared in medium alone and cultures with
osteopontin 50 ng/mL, i.e., the osteopontin level corresponding to the plasma level in healthy stem cell
donors (see Table 1). Osteopontin increased T cell proliferation, but this increase usually corresponded
to less than 20% of the corresponding control cultures both when osteopontin was tested in culture
medium without G-CSF and medium supplemented with G-CSF.
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Figure 5. Peripheral blood mononuclear cells (PBMC) from eight healthy unstimulated donors
were cultured in serum-free medium and stimulated with anti-CD3 and anti-CD28. The effect of
osteopontin 50 ng/mL without G-CSF (left) and with G-CSF 10 pg/mL (right) on in vitro T cell
proliferation was assayed as 3H-thymidi e i corporation expressed as median counts per minute
(cpm). The proliferation of normal PBMC in co trol cultures containing isotypic control antibodies
instead of anti-CD3/anti-CD28 antibodies corresponded to <1000 cpm.
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3. Discussion
Osteopontin can mediate both pro- and anti-inflammatory effects through its binding to
specific receptors expressed by various immunocompetent cells [20,21]. In the present study we
describe that systemic osteopontin levels are altered during stem cell mobilization and harvesting.
Elevated osteopontin levels are detected in the stem cell grafts, and we hypothesize that osteopontin
may thereby affect the immunocompetent cells in the grafts.
Some of the statistically significant differences in osteopontin plasma levels described in our
present study were relatively small. However, the biological day-to-day variation, time of day variation,
and week-to-week variation in osteopontin level in healthy blood donors has been shown to be low [51].
Furthermore, several previous studies have demonstrated that differences corresponding to 15%–25%
of control levels reflect differences of biological and clinical significance, e.g., in cancer patients
and cardiovascular disease patients [52–54]. These observations suggest that even relatively small
variations in plasma osteopontin levels may have a clinical/biological relevance. Our own observations
are also in agreement with these previous observations, e.g., we had similar results in base-line samples
for our two independent groups of healthy individuals.
Our present study compared plasma osteopontin levels in two independent groups of healthy
individuals (G-CSF treated stem cell donors, untreated platelet donors) undergoing apheresis with
or without G-CSF stimulation. Osteopontin concentrations increased during G-CSF treatment, and
the levels showed a further increase after leukapheresis/stem cell harvesting. This was a transient
effect and osteopontin levels decreased during the 24 h period post harvesting. On the other hand, the
control group of healthy untreated platelet donors showed stable osteopontin levels with no detectable
effect of the apheresis.
We also compared the healthy allogeneic stem cell donors with a group of myeloma patients
receiving G-CSF treatment for mobilization of autologous stem cells; the myeloma patients then
showed higher pre-harvesting osteopontin levels and a similar increase as the healthy donors following
leukapheresis. The higher pre-harvesting osteopontin concentrations in myeloma patients may be due
to the combination of G-CSF and chemotherapy for autologous stem cell mobilization in these patients
and five days of treatment with G-CSF in contrast to four days of treatment in the allogeneic donors.
Alternatively, the difference could be disease dependent; increased levels in myeloma patients are
associated with disease burden and decrease when patients respond to anti-myeloma treatment [55,56].
It should be emphasized that only a minority of our patients achieved a complete response prior to the
autologous stem cell harvesting.
Samples drawn prior to G-CSF therapy were not available from our myeloma patients. In a
recent study of myeloma patients mobilized for stem cell harvest, no significant effect of G-CSF on
osteopontin levels could be detected [57]. However, as the regulation of the osteopontin concentration
during stem cell mobilizing in these patients is complex and influenced by both disease stage and
chemotherapy [55], possible effects of G-CSF might be difficult to detect.
Thus, the effect of apheresis (and possibly the effect of G-CSF treatment) on osteopontin levels is
not only seen in healthy donors, but also in myeloma patients. However, the levels were not altered in
healthy blood donors undergoing unstimulated thrombapheresis, which suggests that this is probably
an effect induced by the G-CSF therapy and not a general effect of all kinds of apheresis procedures.
This is further supported by reports of a relatively high degree of product manipulation and activation
in the apheresis device used for platelet collection [58,59]. In contrast to our findings, an eventual
effect of apheresis procedures on osteopontin levels would, therefore, be expected to be stronger
during platelet collection compared to stem cell apheresis. However, it is not possible to exclude that
differences in apheresis techniques between stem cell harvesting and platelet collection (e.g., processed
blood volume, separation techniques, anti-coagulation) contributed to the different effects of apheresis
on osteopontin levels.
G-CSF treatment both in healthy individuals and myeloma patients caused increased levels of
circulating neutrophils that express the osteopontin receptor CD44 [60]. One would, therefore, expect
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increased binding of osteopontin to neutrophils during G-CSF treatment, but despite this increased
binding we could still detect increased osteopontin plasma levels during the treatment.
A recent study of patients with hematological malignancies described an association between
genetic CD44 polymorphisms and the efficiency of CD34+ cell mobilization [61], suggesting that
CD44-osteopontin are important regulators of stem cell retention to the bone marrow during G-CSF
mobilization, at least in myeloma patients. However, we did not observe any association between
osteopontin levels and CD34+ cell mobilization/yield, neither in the myeloma patients, nor in the
healthy stem cell donors.
We investigated the osteopontin levels in the graft supernatants. The high pre-harvesting plasma
levels and the difference between healthy stem cell donors, myeloma patients, and platelet donors
were also reflected in the osteopontin levels in the supernatants. The stem cell transplantation thereby
also includes an infusion of osteopontin.
The osteopontin receptor CD44 is widely expressed by immunocompetent cells; the T cell
expression was not altered by in vivo G-CSF exposure whereas B cell expression was moderately
decreased. Exposure of T cells to osteopontin during in vitro activation caused a slight increase in
anti-CD3 + anti-CD28 initiated T cell proliferation. These experiments show that osteopontin can alter
T cell responses when tested at concentrations corresponding to the in vivo levels. However, additional
studies are required to clarify whether this is a direct stimulatory effect on the proliferating cells, a
reduced effect of T regulatory cells or an indirect effect mediated by the accessory cells.
The highest levels of osteopontin were found in allogeneic stem cell transplant recipients at the
time of transplantation. The levels were high even compared to myeloma patients who had received
both induction therapy and stem cell mobilization, and they were not significantly changed by stem
cell transplantation. This observation indicates that high osteopontin concentrations is one of the
characteristics of the pro-inflammatory state induced by conditioning therapy and underlying disease
in allogeneic stem cell transplant recipients. This pro-inflammatory cytokine balance is considered as
an important basis for development of GVHD [45], and osteopontin blockade is shown to reduce CD8+
T-cell mediated GVHD in mice [46]. Our findings suggest greater importance of the osteopontin
level in the patient compared to the donor and stem cell graft. The osteopontin levels during
conditioning therapy and allogeneic stem cell transplantation in humans and the possible importance
for development of GVHD should be studied in further detail in order to evaluate osteopontin as a
possible therapeutic target in graft versus host disease.
Previous studies have demonstrated that G-CSF has immunomodulatory effects and can suppress
T lymphocytes [62].Such effects are probably important in allotransplant recipients receiving peripheral
blood stem cell grafts because the frequency of GVHD is similar for bone marrow and mobilized
peripheral blood stem cell grafts even though a higher frequency would be expected for the blood
grafts due to their larger number of T cells in these grafts [62]. The molecular mechanisms behind
this are not known, but our present study suggests that effects of osteopontin on immunocompetent
cells may be a part of the G-CSF-induced immunomodulation in healthy stem cell donors. A better
understanding of the mechanisms behind the G-CSF associated immunomodulation will be important
for the future development of therapeutic strategies to target graft T cells and thereby reduce the risk
of severe GVHD without reducing the graft versus leukemia reactivity.
4. Materials and Methods
4.1. Stem Cell Donors and Allotransplant Recipients
All studies were conducted in accordance with the Declaration of Helsinki and approved by the
local ethics committee (REK III No. 126.01, Regional Committee for Medical and Health Research
Ethics of Western Norway: 2008/1580, 2011/996, 2011/1237, 2011/1241, and 2013/634) and donors
and patients were included after signing a written informed consent. The present studies included
(i) 22 consecutive healthy human leukocyte antigen matched (HLA-matched), related, allogeneic
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stem cell donors; (ii) 15 consecutive autologous stem cell donors, all patients with newly-diagnosed
symptomatic multiple myeloma; (iii) 16 allogeneic stem cell transplant recipients; and (iv) 15 healthy
platelet donors (Table 2). The allogeneic stem cell donors did not differ from myeloma patients
and healthy platelet donors with regard to age, gender distribution, or initial peripheral blood
leukocyte count.
4.2. Stem Cell Mobilization in Healthy Donors and Myeloma Patients
The matched related donors received stem cell mobilizing with human non-glycosylated G-CSF
10 µg/kg per day for four days before stem cell harvesting. Initial induction therapy for the myeloma
patients was two cycles of either intravenous cyclophosphamide 1 g/m2 on day 1 at four weeks
intervals (14 patients) or bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 at a three-week interval
(one patient); both regimens were combined with dexamethasone 40 mg orally on days 1–4 and 9–12.
All myeloma patients either responded to the treatment or had stable disease, and stem cells were,
thereafter, mobilized with intravenous cyclophosphamide 2 g/m2 followed by G-CSF 5 µg/kg/day.
Peripheral blood leukocyte counts were significantly higher in healthy stem cell donors compared
to myeloma patients immediately before stem cell harvesting (p < 0.001, Table 2), but the peripheral
blood concentration of CD34+ cells did not differ significantly between groups.
4.3. Apheresis Procedures
Stem cell quantification was started on day 4 or 5 of G-CSF stimulation for stem cell donors
and myeloma patients, respectively. For the myeloma patients this corresponded to day 10 after the
start of cyclophosphamide. Stem cell harvest was performed when the stem cell count exceeded
15–20 ˆ 103/mL. Large-volume leukapheresis with four times processing of the total blood volume
on a Cobe Spectra cell separator, version 7 (Cobe Laboratories, Gloucester, UK) was used for
nine of the healthy stem cell donors and all the myeloma patients; the other 13 healthy stem cell
donors were harvested with a Spectra Optia cell separator, version 9 (Terumo BCT Inc., Lakewood,
CO, USA). The automated mononuclear cells (MNC) procedure was used in accordance with the
instructions from the manufacturer. The yield of CD34+ cells per kg bodyweight obtained by
apheresis and the white blood cell count in the apheresis product did not differ significantly between
groups. Finally, single-donor platelet concentrates from unstimulated healthy volunteer donors were
prepared with a Fenwal Amicus cell separator (Baxter Healthcare Corp., Deerfield, IL, USA) and
leukocyte-reduction provided by elutriation. The platelets were suspended in 37% plasma and 63%
platelet additive solution (T-sol, Baxter Healthcare Corp.) as described in detail previously [63,64].
4.4. Allogeneic Stem Cell Transplantation
Eleven of the 16 allotransplant recipients were diagnosed with acute myeloid leukemia (AML),
three with acute B cell lymphoblastic leukemia (B-ALL), one with myelofibrosis and one with
myelodysplastic syndrome (MDS). All leukemia patients were in complete hematological remission
at the time of transplantation. The patients received (i) myeloablative conditioning with intravenous
busulfan plus cyclophosphamide and mesna (14 patients); or (ii) reduced intensity conditioning
with intravenous fludarabine plus busulfan (two patients). All patients were transplanted with
G-CSF mobilized peripheral blood stem cell grafts derived from HLA-matched family donors and
received graft versus host disease (GVHD) prophylaxis with cyclosporine A, plus methotrexate.
Neutrophil reconstitution was defined as neutrophil counts exceeding 0.2/0.5 ˆ 109/L for at least three
consecutive days, and platelet reconstitution as at least three consecutive days with stable platelet
counts exceeding 20/50 ˆ 109/L.
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4.5. Preparation of Plasma and Peripheral Blood Mononuclear Cells (PBMC)
4.5.1. Blood Sampling
Venous blood samples from the allogeneic stem cell donors were collected (A) prior to G-CSF
stimulation at the time of the pre-transplant evaluation (median 20.5 days before apheresis). For the
three study groups undergoing apheresis, blood samples were also drawn (B) in the morning
immediately before apheresis, (C) immediately after apheresis, and (D) approximately 24 h after
start of apheresis. All venous blood samples from allotransplant recipients were collected between
07:00 and 09:00. Samples for plasma preparation were collected into Vacuette 9NC tubes and samples
for cell preparation into acid-citrate-dextrose solution A (ACD-A) tubes with sodium citrate and
acid-citrate-dextrose solution A as anticoagulants (Greiner Bio-One GmbH, Kremsmünster, Austria).
Samples from stem cell allo- and autografts and platelet concentrates were transferred to plastic tubes
without additives.
4.5.2. Preparation of Plasma Samples
The blood samples were centrifuged at 2000ˆ g (myeloma patients and platelet donors) or
1310ˆ g (allotransplant recipients) for ten minutes at room temperature within 30 min of sampling.
The supernatants were immediately transferred to plastic tubes, frozen, and stored at ´70 ˝C
until analyzed.
4.5.3. Preparation of PBMC Samples
After isolation by density gradient separation (Lymphoprep, AXIS-SHIELD PoC AS, Oslo,
Norway; specific density: 1.077 g/mL), PBMC were dissolved in RPMI 1640 medium supplemented
with 2 mmol/L L-glutamine, penicillin 100 IE/mL, streptomycin 0.1 mg/mL (Sigma-Aldrich, St. Louis,
MO, USA), and 20% fetal bovine serum (FBS, Biowest, Nuaillé, France). 10% dimethyl sulfoxide
(DMSO, Sigma-Aldrich, St. Louis, MO, USA) was used as cryoprotectant, and the vials were stored in
liquid nitrogen at ´150 ˝C after gradual cooling to ´80 ˝C in Mr. Frosty Freezing Container (Thermo
Fisher Scientific, Waltham, MA, USA).
4.6. Analysis of Plasma Osteopontin and G-CSF Concentrations
Plasma osteopontin levels were determined by enzyme-linked immuno-sorbent assays (ELISA)
(Quantikine ELISA Human Osteopontin (OPN) Immunoassay from R&D Systems, Minneapolis,
MN, USA). Plasma G-CSF concentrations were determined by Luminex analyses (R&D Systems,
Minneapolis, MN, USA). All samples were analyzed in duplicates, strictly according to the
manufacturer’s instructions.
4.7. Flow Cytometry Analyses
PBMC were thawed in a 37 ˝C water bath, dissolved in supplemented RPMI 1640 medium, and
incubated for one hour (37 ˝C, a humidified atmosphere of 5% CO2) before incubation with near-IR
fluorescent reactive dye (LIVE/DEAD Fixable Dead Cell Stain Kits, Molecular Probes, Eugene, OR,
USA) for 30 min to determine cell viability. After washing in phosphate-buffered saline (PBS) with
1% bovine serum albumin fraction V (BSA, Roche Diagnostics GmbH, Mannheim, Germany) the cells
were incubated for 20 min with the following mouse anti-human monoclonal antibodies: CD3-PE-Cy7
(SK7), CD4-PerCP-Cy5.5 (RPA-T4), CD8-V500 (RPA-T8), CD19-PerCP-Cy5.5 (SJ25C1), CD45-RA-V450
(HI100), and CD24-PE-Cy7 (ML5) (all from Becton Dickinson Biosciences-BD Pharmingen, San Diego,
CA, USA), rat CD44-Ax 488 (IM7) and mouse CD49b-FITC (P1E6-C5) (both from BioLegend, San Diego,
CA, USA), mouse CD38-PB (HIT2; EXBIO, Prague, Czech Republic) and goat LAG-3-PE (FAB2319P;
R&D Systems, Minneapolis, MN, USA). Eight-color flow cytometry analysis was performed using a
FACS Canto II flow cytometer (Becton Dickinson Biosciences-Immunocytometry Systems; San Jose,
Int. J. Mol. Sci. 2016, 17, 1158 13 of 17
CA, USA). Acquisition of 30,000 CD3+ T cells or 10,000 CD19+ B cells per sample was endeavored,
and cytometer performance was monitored daily with Cytometer Setup and Tracking Beads (Becton
Dickinson Biosciences-BD Pharmingen, San Diego, CA, USA). The data were analyzed with FlowJo
software version X (FlowJo LLC, Ashland, OR, USA).
4.8. Analysis of T-Cell Proliferation by 3H-Thymidine Incorporation
PBMC were cultured in 96-well microtiter plates (5 ˆ 104 cells per well, 190 µL medium per
well), the culture medium being X-vivo10® with 100 µg/mL gentamycin (BioWhittaker, Walkersville,
MA, USA). The T cells were activated by anti-CD3 (clone CLB-T3/4.E, 1XE, PeliCluster, Sanquin,
Amsterdam, The Netherlands; final concentration 316 ng/mL) and anti-CD28 (clone: CLB-CD28/1,
15E8 PeliCluster; final concentration 842 ng/mL). The corresponding control antibodies were
purchased from R&D Systems (Abingdon, UK). The medium was supplemented with recombinant
human osteopontin 50 ng/mL (R&D Systems, Minneapolis, MN, USA) and eventually recombinant
human G-CSF 10 pg/mL (PeproTech EC Ltd., Rocky Hill, NJ, USA). After three days of culture
3H-thymidine (280 kBq per well added in 20 µL of saline; TRA 310, Amersham International,
Amersham, UK) was added and cultures harvested 18 h later. The median count per minute (cpm) of
nuclear radioactivity for triplicate cultures was used for all calculations.
4.9. Statistical Analyses
The statistical analyses were performed by the standard computer software package IBM SPSS
Statistics 22 (IBM Corporate, Armonk, NY, USA). The Wilcoxon’s test for paired samples was applied
for analyses of paired observations, and the independent samples Mann-Whitney U test for comparison
of groups. The covariance between different continuous variables was studied with simple linear
regression analyses with one way analysis of variance (ANOVA).
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G-CSF Granulocyte colony-stimulating factor
CD Cluster of differentiation
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GVHD Graft versus host disease
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HSC Hematopoietic stem cell
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MFI Mean fluorescence intensity
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